Hims & Hers Health (NYSE:HIMS) Insider Irene Becklund Sells 8,410 Shares

Key Points

• Irene Becklund, an insider at Hims & Hers Health, sold 8,410 shares worth $424,705, representing an 85.57% reduction in her position, leaving her with only 1,418 shares valued at $71,609.
• Hims & Hers Health's stock increased by 2.7% to $57.74, with significant trading volume of over 36 million shares, exceeding its average volume.
• Despite a year-over-year revenue increase of 72.6% to $544.83 million, the company reported earnings per share (EPS) of $0.17, missing expectations by $0.01.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Irene Becklund sold 8,410 shares of the company's stock in a transaction that occurred on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total transaction of $424,705.00. Following the completion of the sale, the insider directly owned 1,418 shares of the company's stock, valued at $71,609. The trade was a 85.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Hims & Hers Health Trading Down 0.1%

Shares of HIMS traded down $0.05 during trading hours on Monday, reaching $57.77. The stock had a trading volume of 18,693,929 shares, compared to its average volume of 27,452,044. The company has a market cap of $13.06 billion, a P/E ratio of 72.21, a P/E/G ratio of 3.91 and a beta of 2.14. The firm has a 50-day moving average of $50.83 and a 200 day moving average of $45.92. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. Hims & Hers Health, Inc. has a 52 week low of $16.05 and a 52 week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. During the same period in the prior year, the firm earned $0.06 EPS. The business's revenue for the quarter was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Morgan Stanley reissued an "equal weight" rating and set a $40.00 target price on shares of Hims & Hers Health in a report on Wednesday, June 11th. UBS Group set a $30.00 target price on Hims & Hers Health in a research note on Monday, June 23rd. Zacks Research downgraded Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Finally, Truist Financial reduced their target price on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a research report on Monday, August 18th. Two research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Reduce" and an average price target of $38.92.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors have recently added to or reduced their stakes in the stock. Centaurus Financial Inc. acquired a new stake in Hims & Hers Health in the second quarter valued at approximately $171,000. Thrivent Financial for Lutherans grew its position in Hims & Hers Health by 3.6% during the 2nd quarter. Thrivent Financial for Lutherans now owns 46,444 shares of the company's stock worth $2,315,000 after acquiring an additional 1,617 shares during the last quarter. Marex Group plc bought a new position in Hims & Hers Health in the second quarter valued at about $53,626,000. Nomura Holdings Inc. boosted its stake in shares of Hims & Hers Health by 151.4% during the second quarter. Nomura Holdings Inc. now owns 161,052 shares of the company's stock valued at $8,028,000 after purchasing an additional 96,997 shares in the last quarter. Finally, Castleark Management LLC bought a new stake in shares of Hims & Hers Health during the second quarter worth about $2,921,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.